China
Africa
Explore chapters and articles related to this topic
Causes and risk factors
Published in Janetta Bensouilah, Pregnancy Loss, 2021
Hereditary thrombophilias are a group of genetic coagulation disorders. Specific gene mutations make the carriers more susceptible to developing thrombosis, and although not everyone with a blood-clotting disorder will experience pregnancy loss or any clinical manifestations at all, a number of studies demonstrate strong associations with obstetric complications, including late miscarriage (seeBox 2.1). Thrombophilias increase the risk of placental abruption, IUGR, severe pre-eclampsia, iatrogenic preterm labour, excessive intrapartum and postpartum haemorrhage, antenatal and postpartum deep vein thrombophlebitis and pulmonary embolism.3 Although there are known links between hereditary clotting disorders and pregnancy loss, this alone does not determine which women will develop pregnancy complications. It is apparent from the data currently available that multiple factors are involved in determining who is affected. Identification of a specific gene mutation in an individual may not necessarily provide the single reason (or treatment) for their pregnancy loss.
Genital
Published in Keith Hopcroft, Vincent Forte, Symptom Sorter, 2020
OCCASIONAL blood clotting disorder or anticoagulationcalculi in the prostatecarcinoma: prostate, testicles, bladder or seminal vesicles
Neurology
Published in Timothy Williamson, Lesley Thoms, The Practical Pocket Guide to History Taking and Clinical Examination, 2014
Timothy Williamson, Lesley Thoms
Do you have . . . high blood pressurediabetes mellituscardiac disease (including atrial fibrillation)blood clotting disordercancer?
The Toxic Effects of Ethylene Glycol Tetraacetate Acid, Ferrum Lek and Methanol on the Glutathione System: correction Options
Published in Expert Review of Clinical Pharmacology, 2021
Valproate sodium is a common broad-spectrum antiepileptic drug used to treat various forms of epilepsy. Approximately 11% of patients, who took sodium valproate, demonstrated an asymptomatic increase in transaminase activity, which decreased with lower doses or drug withdrawal. However, it may cause severe to lethal hepatic reactions, mostly in children and young people aged 2.5 months to 34 years. Sixty-nine percent of cases involved patients under the age of 10. First symptoms appear within 1–2 months after the intake period starts and do not occur after 6–12 months of treatment. The first manifestation includes vomiting and impaired consciousness alongside hypoglycemia and blood clotting disorders. Additionally, one may detect other signs. Aside from that, the electron microscopy revealed mitochondrial damage [34,35].
Surgical Management of Haemophilic Pseudotumors: Experience in a Developing Country
Published in Journal of Investigative Surgery, 2019
Yu He, Xi Zhou, Haomin Cui, Guixing Qiu, Xisheng Weng, Baozhong Zhang, Yong Liu
Hemophilia is a blood clotting disorder caused by an X-linked recessive mutation in the factor VIII or IX gene.1 Hemophilic pseudotumor is an encapsulated hematoma resulting of repeated episodes of bleeding in the bone, subperiosteum, or soft tissue.2–4 As it expands, the increasing pressure within the hematoma results in the slow destruction of adjacent structures.5 The symptomatic presence of an enlarging mass in limb, pelvis, or abdomen can cause severe pain, restriction of movement, nervous impairment, bowel obstruction, renal and ureteral compression, and fistula.6–9 Bleeding is a significant complication in these patients, and the leading cause of morbidity and mortality. Therefore, therapeutic strategies are required by hematologists, orthopedic surgeons, physiotherapists, and other members of the team who have collaborated and participated in hemophilic surgery.
Platelet function assays in diagnosis: an update
Published in Expert Review of Hematology, 2019
Paolo Gresele, Loredana Bury, Anna Maria Mezzasoma, Emanuela Falcinelli
When the preliminary clinical evaluation is suggestive of an IPFD, an initial laboratory screening to exclude non platelet-dependent causes of bleeding (like von Willebrand disease or blood clotting disorders) should be performed [9]. If the initial screening is negative, the patient should undergo platelet-function testing after being advised to discontinue all possibly interfering drugs before blood drawing. It must be borne in mind, however, that rare cases of combined IPFD and blood clotting disorders have been reported [7] therefore, in patients with mild VWD (or other mild coagulation disorders) and disproportionate bleeding manifestations, or in patients who can not discontinue medications interfering with coagulation, laboratory investigation of platelet function is still advisable [1].